Evidence map›Paper›PMID 36453881›Full record

ArticleJournal of virology2022

Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.

Tawanda Mandizvo, Nombali Gumede, Bongiwe Ndlovu, Siphiwe Ndlovu, Jaclyn K Mann, Denis R Chopera, Lanish Singh, Krista L Dong, Bruce D Walker, Zaza M Ndhlovu and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Tawanda MandizvoAfrica Health Research Institute, Durban, South Africa.ORCID 0000-0003-3482-9768
Nombali GumedeHIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natalgrid.16463.36, Durban, South Africa.
Bongiwe NdlovuHIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natalgrid.16463.36, Durban, South Africa.
Siphiwe NdlovuHIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natalgrid.16463.36, Durban, South Africa.ORCID 0000-0002-4903-5875
Jaclyn K MannHIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natalgrid.16463.36, Durban, South Africa.
Denis R ChoperaAfrica Health Research Institute, Durban, South Africa.
Lanish SinghAfrica Health Research Institute, Durban, South Africa.
Krista L DongRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, Massachusetts, USA.
Bruce D WalkerHIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natalgrid.16463.36, Durban, South Africa.
Zaza M NdhlovuAfrica Health Research Institute, Durban, South Africa.
Christy L LavineCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.
Kamini GounderAfrica Health Research Institute, Durban, South Africa.ORCID 0000-0002-1674-6021
Thumbi Ndung'uAfrica Health Research Institute, Durban, South Africa.ORCID 0000-0003-2962-3992
Africa Health Research Institute · ZARagon Institute of MGH, MIT and Harvard · USUniversity of KwaZulu-Natal · ZABeth Israel Deaconess Medical Center · US

Funding

Pathogenesis of Clade C HIV InfectionR37AI067073 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2011 to 2020
$6.6M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R37AI067073Wellcome Trust 107752/Z/15/Z
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bNAbs) for HIV-1 prevention or cure strategies must inhibit transmitted/founder and reservoir viruses. Establishing sensitivity of circulating viruses to bNAbs and genetic patterns affecting neutralization variability may guide rational bNAbs selection for clinical development. We analyzed 326 single

Indexed as

env Gene Products, Human Immunodeficiency VirusHIV InfectionsBroadly Neutralizing AntibodiesEpitopesHIV-1HIV AntibodiesHumansPhylogenyBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusEpitopesHIV Antibodiesacute HIV-1 infectionbNAbsHIV-1 envelopeHIV-1 intraparticipant diversityHIV-1 subtype Clongitudinal HIV-1 diversitysensitivity to bNAbs

Identifiers

PMID36453881
PMCPMC9769376
OpenAlexW4310570357

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.